Basaran Kemal Erdem, Villongco Michael, Ho Baran, Ellis Erika, Zarndt Rachel, Antonova Julie, Hopkins Susan R, Powell Frank L
Division of Physiology, Department of Medicine, University of California San Diego, San Diego, California, United States of America.
Department of Medical Physiology, Faculty of Medicine, Erciyes University, Melikgazi, Kayseri, Turkey.
PLoS One. 2016 Jan 4;11(1):e0146087. doi: 10.1371/journal.pone.0146087. eCollection 2016.
Ventilatory acclimatization to hypoxia is a time-dependent increase in ventilation and the hypoxic ventilatory response (HVR) that involves neural plasticity in both carotid body chemoreceptors and brainstem respiratory centers. The mechanisms of such plasticity are not completely understood but recent animal studies show it can be blocked by administering ibuprofen, a nonsteroidal anti-inflammatory drug, during chronic hypoxia. We tested the hypothesis that ibuprofen would also block the increase in HVR with chronic hypoxia in humans in 15 healthy men and women using a double-blind, placebo controlled, cross-over trial. The isocapnic HVR was measured with standard methods in subjects treated with ibuprofen (400 mg every 8 hrs) or placebo for 48 hours at sea level and 48 hours at high altitude (3,800 m). Subjects returned to sea level for at least 30 days prior to repeating the protocol with the opposite treatment. Ibuprofen significantly decreased the HVR after acclimatization to high altitude compared to placebo but it did not affect ventilation or arterial O2 saturation breathing ambient air at high altitude. Hence, compensatory responses prevent hypoventilation with decreased isocapnic ventilatory O2-sensitivity from ibuprofen at this altitude. The effect of ibuprofen to decrease the HVR in humans provides the first experimental evidence that a signaling mechanism described for ventilatory acclimatization to hypoxia in animal models also occurs in people. This establishes a foundation for the future experiments to test the potential role of different mechanisms for neural plasticity and ventilatory acclimatization in humans with chronic hypoxemia from lung disease.
对低氧的通气适应是通气和低氧通气反应(HVR)随时间的增加,这涉及颈动脉体化学感受器和脑干呼吸中枢的神经可塑性。这种可塑性的机制尚未完全了解,但最近的动物研究表明,在慢性低氧期间给予布洛芬(一种非甾体抗炎药)可以阻断它。我们在15名健康男性和女性中进行了一项双盲、安慰剂对照、交叉试验,以检验布洛芬也会阻断人类慢性低氧时HVR增加的假设。采用标准方法在海平面和高海拔(3800米)分别用布洛芬(每8小时400毫克)或安慰剂治疗受试者48小时,测量其等碳酸血症时的HVR。在采用相反治疗方案重复该实验之前,受试者返回海平面至少30天。与安慰剂相比,布洛芬在受试者适应高海拔后显著降低了HVR,但在高海拔环境空气中呼吸时,它并未影响通气或动脉血氧饱和度。因此,在这个海拔高度,代偿反应可防止因布洛芬导致的等碳酸血症通气氧敏感性降低而引起的通气不足。布洛芬降低人类HVR的作用提供了首个实验证据,表明动物模型中描述的低氧通气适应信号机制在人类中也存在。这为未来实验奠定了基础,以测试不同神经可塑性和通气适应机制在患有慢性低氧血症的肺病患者中的潜在作用。